Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678978 | 0.82 | KMT2A (0.56) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL118108 | 0.82 | KMT2A (0.56) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29402075 | 0.82 | KMT2A (0.56) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL7872045 | 0.81 | HCAR3 (0.51) | KMT2AEPHX2FABP7FABP5MDM4 | |
| Benzoic Acid SCHEMBL27028192 | 0.80 | KMT2A (0.56) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL346077 | 0.80 | KMT2A (0.52) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL1855193 | 0.79 | EPHX2 (0.53) | KMT2AEPHX2 | |
| SCHEMBL22498215 | 0.79 | KMT2A (0.55) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL7920181 | 0.78 | KMT2A (0.52) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL3177417 | 0.78 | KMT2A (0.62) | KMT2AEPHX2FABP7FABP5CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003959-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Bayer AS (NO) | 2022-06-01 | — | — | EP | disclosed |